Business Description
Pharmigene Inc
ISIN : TW0007595B13
Share Class Description:
ROCO:7595: Ordinary SharesDescription
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.54 | |||||
| Debt-to-EBITDA | -10.77 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.81 | |||||
| Beneish M-Score | -2.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.9 | |||||
| 3-Year EPS without NRI Growth Rate | -72.8 | |||||
| 3-Year FCF Growth Rate | -194 | |||||
| 3-Year Book Growth Rate | -2.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.45 | |||||
| 9-Day RSI | 50.81 | |||||
| 14-Day RSI | 49.67 | |||||
| 6-1 Month Momentum % | -11.46 | |||||
| 12-1 Month Momentum % | -26.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.13 | |||||
| Quick Ratio | 5.24 | |||||
| Cash Ratio | 4.05 | |||||
| Days Inventory | 119.83 | |||||
| Days Sales Outstanding | 54.17 | |||||
| Days Payable | 28.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.1 | |||||
| Shareholder Yield % | -33.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.12 | |||||
| Operating Margin % | -58.83 | |||||
| Net Margin % | -72.92 | |||||
| FCF Margin % | -112.67 | |||||
| ROE % | -23.93 | |||||
| ROA % | -9.3 | |||||
| ROIC % | -8.89 | |||||
| 3-Year ROIIC % | -6.35 | |||||
| ROC (Joel Greenblatt) % | -12.36 | |||||
| ROCE % | -8.41 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.02 | |||||
| PB Ratio | 2.1 | |||||
| Price-to-Tangible-Book | 2.17 | |||||
| EV-to-EBIT | -15.86 | |||||
| EV-to-EBITDA | -22.76 | |||||
| EV-to-Revenue | 10 | |||||
| EV-to-FCF | -9.3 | |||||
| Earnings Yield (Greenblatt) % | -6.31 | |||||
| FCF Yield % | -17.52 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers